| A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (NCT06567041) | Novo Nordisk A/S | 2024-08-07 |
| Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease (NCT06422208) | Penelope J. Hallett, Ph.D. | 2024-08-07 |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (NCT06292780) | Regeneron Pharmaceuticals | 2024-08-07 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (NCT06445972) | Merck Sharp & Dohme LLC | 2024-08-07 |
| Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT06162572) | Servier Bio-Innovation LLC | 2024-08-07 |
| Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) (NCT06219174) | H. Lee Moffitt Cancer Center and Research Institute | 2024-08-07 |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone (NCT06225310) | Oncotherapeutics | 2024-08-06 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (NCT06469281) | Regeneron Pharmaceuticals | 2024-08-06 |
| CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults (NCT06485258) | Centers for Disease Control and Prevention | 2024-08-06 |
| A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants. (NCT06531811) | AstraZeneca | 2024-08-06 |
| A Study of SGB-9768 in Adult Healthy Volunteers (NCT06501573) | Suzhou Sanegene Bio Inc. | 2024-08-06 |
| A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. (NCT06487455) | Shanghai Pharmaceuticals Holding Co., Ltd | 2024-08-06 |
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis (NCT06400303) | Kyverna Therapeutics | 2024-08-06 |
| A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers (NCT06527755) | AstraZeneca | 2024-08-06 |
| A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer (NCT05963867) | Boehringer Ingelheim | 2024-08-06 |
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia (NCT06401603) | M.D. Anderson Cancer Center | 2024-08-06 |
| A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants (NCT06438263) | Amgen | 2024-08-06 |
| Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial (NCT06447415) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-08-06 |
| Study of XB010 in Subjects With Solid Tumors (NCT06545331) | Exelixis | 2024-08-06 |
| A Phase I Study of LX22001 for Injection in Healthy Subjects (NCT06561542) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2024-08-05 |
| A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants (NCT06554821) | AstraZeneca | 2024-08-05 |
| A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects (NCT06549959) | RemeGen Co., Ltd. | 2024-08-05 |
| Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment (NCT04807257) | NanoRay Biotech Co., Ltd. | 2024-08-05 |
| Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT06308588) | M.D. Anderson Cancer Center | 2024-08-05 |
| A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants (NCT06511076) | UCB Biopharma SRL | 2024-08-05 |
| CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 (NCT06152172) | David Porter | 2024-08-05 |
| A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets (NCT07193576) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-08-04 |
| Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia (NCT05720988) | Jonsson Comprehensive Cancer Center | 2024-08-03 |
| Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations (NCT07121868) | Aya Mohammed Abdel Magid Abdel Hamid | 2024-08-03 |
| A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer (NCT06776770) | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 2024-08-03 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years (NCT06454175) | Shanghai Bovax Biotechnology Co., Ltd. | 2024-08-03 |
| tDCS and Cognitive Training for Restrictive Eating Disorders (NCT06624150) | University of Minnesota | 2024-08-02 |
| VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI) (NCT06533280) | ViiV Healthcare | 2024-08-02 |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer (NCT05898828) | National Cancer Institute (NCI) | 2024-08-02 |
| Study of STP938 (Dencatistat) in Advanced Solid Tumours (NCT06297525) | Step Pharma, SAS | 2024-08-02 |
| Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis (NCT06298019) | Stanford University | 2024-08-02 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors (NCT06466187) | Seagen, a wholly owned subsidiary of Pfizer | 2024-08-02 |
| A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors (NCT06505824) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-08-02 |
| Racecadotril Versus Standard Treatment in Decreasing the Duration of Acute Diarrhoea in Children (NCT06529497) | Liaquat National Hospital & Medical College | 2024-08-02 |
| Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma (NCT06611150) | Sun Yat-sen University | 2024-08-02 |
| Restoration of the Gut Microbiome After Cesarean Section (NCT06264219) | Jakob Stokholm | 2024-08-02 |
| A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 (NCT06592482) | AstraZeneca | 2024-08-02 |
| A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants (NCT06502379) | AstraZeneca | 2024-08-02 |
| Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment (NCT06529796) | Vertex Pharmaceuticals Incorporated | 2024-08-02 |
| A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight (NCT06547775) | Suzhou Alphamab Co., Ltd. | 2024-08-02 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia (NCT06523556) | Uma Borate | 2024-08-02 |
| Role of Salbutamol in the Management of Transient Tachypnea of the New Born (NCT06921291) | Khyber Teaching Hospital | 2024-08-01 |
| RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors (NCT06545201) | Henan Cancer Hospital | 2024-08-01 |
| Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye (NCT06543667) | Iran University of Medical Sciences | 2024-08-01 |
| Effect of Food of NTQ5082 in Healthy Subjects (NCT06558656) | Nanjing Chia-tai Tianqing Pharmaceutical | 2024-08-01 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects (NCT06918366) | Brilliant Inspiration Biotherapeutics | 2024-08-01 |
| A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers (NCT06560593) | Nanjing Chia-tai Tianqing Pharmaceutical | 2024-08-01 |
| Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects (NCT06454708) | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | 2024-08-01 |
| Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (NCT06327100) | M.D. Anderson Cancer Center | 2024-08-01 |
| Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant (NCT06609980) | Rutgers, The State University of New Jersey | 2024-08-01 |
| Stem Cell Derived Exome for Treatment of Diabetic Foot (NCT06480123) | Second Affiliated Hospital of Guangzhou Medical University | 2024-08-01 |
| Study of the Drug B11-FC (Botulism Treatment) (NCT06580236) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2024-08-01 |
| 3Mixtatin and MTA Vital Pulpotomy in Primary Molars (NCT06478940) | Cairo University | 2024-08-01 |
| Dorsal Nerve Block and Caudal Block in Hypospedius Repair in Children (NCT06500286) | Assiut University | 2024-08-01 |
| Effects of Exosome Adminstration in Preventing Early Leakage in Rectal Cancer Patients Undergoing Low Anterior Resection (NCT06536712) | Tehran University of Medical Sciences | 2024-08-01 |
| Clinical Assessment of Chitosan Nanoparticles on Periodontal Problems Post Steroidal Inhalation in Asthmatic Patients: Phase I Trial (NCT06525363) | Deraya University | 2024-08-01 |
| Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi) (NCT06296056) | Seoul Hospital | 2024-08-01 |
| Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia (NCT07513038) | Boston Children's Hospital | 2024-08-01 |
| COMPARISON OF BUPIVACAINE WITH AND WITHOUT DEXMEDETOMIDINE IN CAUDAL BLOCK AMONG CHILDREN UNDERGOING INGUINAL HERNIOTOMY (NCT07140627) | Allama Iqbal Medical College | 2024-08-01 |
| Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating Acute Ischemic Stroke (NCT06518902) | National Engineering Center of Cell Products | 2024-08-01 |
| Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension (NCT06518850) | Peking Union Medical College Hospital | 2024-08-01 |
| Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors (NCT06533605) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-08-01 |
| Pilot Study of Preoperative Intestinal Training Using Antegrade Ileostomy Infusion (NCT06461559) | University of California, San Diego | 2024-08-01 |
| Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) (NCT06100276) | UniQure Biopharma B.V. | 2024-08-01 |
| Effect of Fluid Resuscitation on Lactate in Traumatic Injury Patients (NCT06370975) | Assiut University | 2024-08-01 |
| A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects (NCT06422624) | Bostal Drug Delivery Co., Ltd | 2024-08-01 |
| Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (NCT06522035) | Enlivex Therapeutics Ltd. | 2024-08-01 |
| Impact of Early ADL Education on Outcomes Post DRF ORIF (NCT06251206) | George Washington University | 2024-08-01 |
| MB-dNPM1-TCR.1 in Relapsed/Refractory AML (NCT06424340) | Miltenyi Biomedicine GmbH | 2024-08-01 |
| Establishing Best Treatment Strategy for T4 Esophageal Cancer (NCT06531434) | National Cheng-Kung University Hospital | 2024-08-01 |
| Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (NCT06421701) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-01 |
| Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT (NCT07660406) | Peking Union Medical College Hospital | 2024-08-01 |
| Bioequivalence Study of AG2202 (NCT06549504) | Ahn-Gook Pharmaceuticals Co.,Ltd | 2024-08-01 |
| Exenatide For Reducing the Reinforcing Effects of Cocaine (NCT06252623) | Christopher D. Verrico | 2024-08-01 |
| Targeted Survivin DC Cell Injection for the Treatment of GBM (NCT06524063) | Beijing Tricision Biotherapeutics Inc | 2024-08-01 |
| Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease (NCT06399107) | Essen Biotech | 2024-08-01 |
| Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects (NCT06511947) | GH Research Ireland Limited | 2024-08-01 |
| Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) (NCT06454890) | Henan Cancer Hospital | 2024-08-01 |
| γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors (NCT06404281) | Changzhou No.2 People's Hospital | 2024-08-01 |
| Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin (NCT06490198) | Chang Gung Memorial Hospital | 2024-07-31 |
| Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults (NCT06523595) | Vertex Pharmaceuticals Incorporated | 2024-07-31 |
| Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma (NCT06494189) | West China Hospital | 2024-07-31 |
| Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies (NCT06528249) | Zhejiang Provincial People's Hospital | 2024-07-31 |
| SW-682 in Advanced Solid Tumors (NCT06251310) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2024-07-31 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects (NCT06563713) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2024-07-31 |
| Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer (NCT06331169) | Fudan University | 2024-07-31 |
| A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants (NCT06555601) | UCB Biopharma SRL | 2024-07-31 |
| Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects (NCT06501586) | Suzhou Sanegene Bio Inc. | 2024-07-31 |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (NCT06147037) | AstraZeneca | 2024-07-31 |
| Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (NCT06417853) | Vaxxas Pty Ltd | 2024-07-31 |
| On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma (NCT06503211) | The First Affiliated Hospital with Nanjing Medical University | 2024-07-31 |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets (NCT06474650) | Luye Pharma Group Ltd. | 2024-07-31 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders (NCT06434363) | M.D. Anderson Cancer Center | 2024-07-31 |
| A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults (NCT06442241) | Guangzhou Patronus Biotech Co., Ltd. | 2024-07-31 |
| Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) (NCT06530810) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2024-07-31 |